Answers are grounded in this paper and cite their sources.
Background: Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of advanced or metastatic melanoma in recent years, with patients experiencing durable responses to treatment. These patients face specific QoL challenges. The QUALICI study aimed to assess patients’ QoL, their experiences, and expectations about QoL management.
No takes yet. Share an insight, caveat, or question.
Robert et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: